EGFr
Showing 1 - 25 of 5,630
NSCLC, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial (Nintedanib, gefitinib, erlotinib, afatinib)
Not yet recruiting
- Non-small Cell Lung Cancer
- +2 more
- Nintedanib, gefitinib, erlotinib, afatinib
- (no location specified)
Oct 2, 2023
Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant
Completed
- The Primary Study Metric is Progression-free Survival (PFS)
- (no location specified)
Jun 28, 2023
EGFR Mutant Advanced NSCLC Trial (BBT-207)
Not yet recruiting
- EGFR Mutant Advanced Non-Small Cell Lung Cancer
- (no location specified)
Jun 16, 2023
NSCLC Trial in Singapore (Afatinib 40 MG)
Not yet recruiting
- NSCLC
- Afatinib 40 MG
-
Singapore, SingaporeNational University Hospital
Sep 25, 2023
IASLC Grading System as a Predictor for EGFR-TKI Therapy
Completed
- Lung Cancer
- IASLC grading system
-
Shanghai, Please Select, ChinaChaoqiang Deng
Nov 9, 2023
Solid Tumor, EGFR Amplification Trial in Tianjin (Nimotuzumab)
Recruiting
- Solid Tumor
- EGFR Amplification
-
Tianjin, Tianjin, ChinaTianjin Medical University Second Hospital
Aug 28, 2023
Lung Cancer Trial in Boston, Nashville
Active, not recruiting
- Lung Cancer
-
Boston, Massachusetts
- +1 more
Dec 28, 2022
Cancer, Solid Tumor, Colorectal Cancer Trial (biological, radiation, drug)
Not yet recruiting
- Cancer
- +8 more
- DK210 (EGFR)
- +3 more
- (no location specified)
Jan 27, 2023
Brain Metastases, NSCLC Trial in Shanghai (EGFR-TK Inhibitor, Stereotactic radiotherapy)
Recruiting
- Brain Metastases
- Non-small Cell Lung Cancer
- EGFR-TK Inhibitor
- Stereotactic radiotherapy
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Aug 27, 2023
Nasopharyngeal Carcinoma Trial in Shanghai (Anti-EGFR and PD-1 inhibitor arm)
Recruiting
- Nasopharyngeal Carcinoma
- Anti-EGFR and PD-1 inhibitor arm
-
Shanghai, Shanghai, ChinaEye & ENT Hospital of Fudan University
Nov 26, 2023
Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)
Not yet recruiting
- Non Squamous Non Small Cell Lung Cancer
- EGFR Positive Non-small Cell Lung Cancer
- Toripalimab plus Chemotherapy
- (no location specified)
Jul 28, 2023
EGF-R Positive NSCLC, Non Small Cell Lung Cancer, EGFR Exon 19 Deletion Trial in Bogotá (Stereotactic Body Radiation Therapy
Not yet recruiting
- EGF-R Positive Non-Small Cell Lung Cancer
- +4 more
- Stereotactic Body Radiation Therapy SBRT
-
Bogotá, ColombiaCTIC - Centro de Tratamiento e Investigación Sobre Cáncer Luis C
Aug 16, 2023
NSCLC, EGFR Gene Mutation Trial in Nanjing (neo-antigen vaccine)
Recruiting
- NSCLC
- EGFR Gene Mutation
- neo-antigen vaccine
-
Nanjing, ChinaThe Comprehensive Cancer Centre of Nanjing Drum Tower Hospital,
Oct 19, 2023
NSCLC, EGFR Activating Mutation, Brain Metastases Trial in Beijing (TY-9591, Osimertinib)
Not yet recruiting
- NSCLC
- +2 more
-
Beijing, Beijing, ChinaNational Cancer Center/Cancer Hospitial,Chinese Academy of Medic
Jul 9, 2023
NSCLC?EGFR Sensitive Mutation Trial in Bengbu, Changsha, Shanghai (MCLA-129: 1500mg or 2000mg IV Q2W, Befotertinib: 75 mg or 100
Not yet recruiting
- Non-Small Cell Lung Cancer、EGFR Sensitive Mutation
- MCLA-129: 1500mg or 2000mg IV Q2W
- Befotertinib: 75 mg or 100 mg Po QD
-
Bengbu, Anhui, China
- +2 more
Aug 28, 2023
Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC
Recruiting
- Non-small Cell Lung Cancer
-
Guanzhou, ChinaSun Yat-sen University Cancer Center
Aug 11, 2023
CNS Tumor, Pediatric, Glioma, Ependymoma Trial in Seattle (EGFR806-specific chimeric antigen receptor (CAR) T cell)
Active, not recruiting
- Central Nervous System Tumor, Pediatric
- +8 more
- EGFR806-specific chimeric antigen receptor (CAR) T cell
-
Seattle, WashingtonSeattle Children's Hospital
Jan 18, 2023
NSCLC, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation Trial in Fairfax (STX-721)
Not yet recruiting
- Non-Small Cell Lung Cancer
- +2 more
-
Fairfax, VirginiaNEXT Virginia
Sep 18, 2023
Brain Metastases, Radiotherapy, EGFR Activating Mutation Trial in Guangdong (brain radiotherapy, Almonertinib)
Recruiting
- Brain Metastases
- +2 more
- brain radiotherapy
- Almonertinib
-
Guangdong, Guangzhou, ChinaSun-Yat-Sen university
Mar 13, 2023